Physician profile
Douglas C Smith
NPI 1669440798
$2,282.67
in general payments reported to CMS, 2019-2025
23 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $98.08 · 2021: $14.61 · 2022: $70.32 · 2023: $781 · 2024: $341 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $436.49 | 2023-2025 | |
| Horizon Therapeutics Plc | $236.94 | 2019-2021 | |
| Abbvie INC. | $223.49 | 2025 | |
| Smith+Nephew, INC. | $193.16 | 2023-2025 | Grafix Pl, Stravix Pl, Stravix |
| Nevro Corp. | $156.44 | 2023 | Senza |
| Lifenet Health | $149.11 | 2025 | Theragenesis Wound Matrix |
| Amgen INC. | $142.90 | 2024-2025 | Krystexxa |
| Bioventus LLC | $133.82 | 2022-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Integra Lifesciences Corporation | $126.08 | 2023 | Tenoglide |
| In2bones USA, LLC | $94.20 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $42.40 | 2025 | |
| Melinta Therapeutics, LLC | $41.57 | 2019 | |
| Depuy Synthes Sales INC. | $40.27 | 2024-2025 | Motoband |
| Medtronic, INC. | $38.78 | 2025 | Inceptiv |
| Abbott Laboratories | $37.84 | 2023 | Proclaim |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $35.91 | 2024 | Licart, Tirosint |
| Paratek Pharmaceuticals, INC. | $30.20 | 2022-2024 | Nuzyra |
| Sebela Pharmaceuticals INC. | $28.52 | 2023 | Naftin |
| Acera Surgical, INC. | $25.41 | 2024 | Restrata Wound Matrix |
| Mimedx Group, INC. | $22.66 | 2025 | |
| Fidia Pharma USA INC. | $18.35 | 2022 | |
| Organogenesis INC. | $17.18 | 2025 | Puraply Wound Matrix |
| Next Science LLC | $10.95 | 2023 | Surgx, Xperience, Blastx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.